OncoMatch

OncoMatch/Clinical Trials/NCT06826768

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Is NCT06826768 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including REGN5678 and Cemiplimab for prostate cancer.

Phase 1RecruitingM.D. Anderson Cancer CenterNCT06826768Data as of Jun 2026

Treatment: REGN5678 · CemiplimabA single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Cemiplimab

Other

REGN5678

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Male only

Prior therapy

Min 2 prior lines

Must have received: antiandrogen — second-generation

disease progression after at least two lines of systemic therapy, including one line of second-generation anti-androgen therapy

Lab requirements

Blood counts

Hemoglobin ≥8.5 g/dL; ANC ≥1.0 x 10^9/L; Platelet count ≥100 x 10^9/L

Kidney function

Serum creatinine ≤1.5 x ULN or estimated GFR >50 mL/min/1.73 m2

Liver function

Total bilirubin ≤1.5 x ULN (except Gilbert's syndrome); AST ≤2.5 x ULN; ALT ≤2.5 x ULN; ALP ≤2.5 x ULN (≤5 x ULN if tumor liver or bone involvement)

Adequate organ and bone marrow function documented by: Hemoglobin ≥8.5 g/dL; ANC ≥1.0 x 10^9/L; Platelet count ≥100 x 10^9/L. Serum creatinine ≤1.5 x ULN or estimated GFR >50 mL/min/1.73 m2. Adequate hepatic function: Total bilirubin ≤1.5 x ULN; AST ≤2.5 x ULN; ALT ≤2.5 x ULN; ALP ≤2.5 x ULN (≤5 x ULN if tumor liver or bone involvement).

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • The University of Texas M. D. Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06826768 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received antiandrogen.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify